The registry aims to document epidemiologic data, treatment and long-term outcome as well as quality of life of patients with APL. Additionally, a biobanking project for further translational studies is integrated. Prospective population-based non-interventional and non-randomized multicenter registry.
* collection of epidemiological data for APL: age distribution, prognostic factors, distribution of subgroups, incidence * documentation of efficacy and safety of the first line and salvage therapy in APL including * documentation of minimal residual disease (MRD) * correlation of clinical outcomes with chosen therapy * collection and evaluation of quality of life * validation of published prognostic factors / new potential prognostic factors * acquisition of bone marrow, peripheral blood and buccal swab samples for biobanking and translational studies under the umbrella of the specific study-group biobanking concepts
Study Type
OBSERVATIONAL
Enrollment
500
Prof. Dr. U. Platzbecker
Dresden, Germany
RECRUITINGepidemiological parameters
Time frame: yearly follow up for 5 years
diagnostic quality indicators
Time frame: yearly follow up for 5 years
type of therapy
Time frame: yearly follow up for 5 years
response, recurrence and time of death and resulting outcomes RFS and OS
Time frame: yearly follow up for 5 years
complete remission (CR) and CRm
Time frame: yearly follow up for 5 years
treatment related mortality (TRM)
Time frame: yearly follow up for 5 years
cumulative incidence of relapse (CIR)
Time frame: yearly follow up for 5 years
grade IV toxicities
Time frame: yearly follow up for 5 years
quality of life (QoL): EORTC QLQ-C30
Time frame: yearly follow up for 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.